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AIMS
Although genetic, clinical and demographic factors have been shown
to explain approximately half of the inter-individual variability in
warfarin dose requirement in adults, less is known about causes of
dose variability in children. This study aimed to identify and quantify
major genetic, clinical and demographic sources of warfarin dose
variability in children using modelling and simulation.
METHODS
Clinical, demographic and genetic data from 163 children with a
median age of 6.3 years (range 0.06–18.9 years), covering over 183
years of warfarin therapy and 6445 INR observations were used to
update and optimize a published adult pharmacometric warfarin
model for use in children.
RESULTS
Genotype effects in children were found to be comparable with what
has been reported for adults, with CYP2C9 explaining up to a four-fold
difference in dose (CYP2C9 *1/*1 vs. *3/*3) and VKORC1 explaining up
to a two-fold difference in dose (VKORC1 G/G vs. A/A), respectively. The
relationship between bodyweight and warfarin dose was non-linear,
with a three-fold difference in dose for a four-fold difference in
bodyweight. In addition, age, baseline and target INR, and time since
initiation of therapy, but not CYP4F2 genotype, had a significant
impact on typical warfarin dose requirements in children.
CONCLUSIONS
The updated model provides quantitative estimates of major clinical,
demographic and genetic factors impacting on warfarin dose
variability in children. With this new knowledge more individualized
dosing regimens can be developed and prospectively evaluated in the
pursuit of improving both efficacy and safety of warfarin therapy in
children.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Genetic, clinical and demographic factors
collectively make a significant contribution
to the inter-individual variability in warfarin
dose requirement in adults.
• Less is known about the major causes of
warfarin dose variability in children,
including the relative importance of genetic,
clinical and demographic factors.
WHAT THIS STUDY ADDS
• This study shows that CYP2C9 and VKORC1
genotype, bodyweight, age, baseline and
target INR, and time since initiation of
therapy, but not CYP4F2 genotype, are
significant causes of warfarin dose variability
in children.
• The model can provide the basis for
development of more individualized
warfarin dosing in children.
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Introduction
Warfarin is the most commonly prescribed anticoagulant
in both adults and children [1]. Although it has been in
clinical use for over 60 years, warfarin therapy is still a
clinical challenge due to the drug’s narrow therapeutic
range and large inter- and intra-individual variability in
response to a fixed dose. Known factors contributing to
the variability in dose requirement in adults include age,
body size, co-morbidities, co-medications, vitamin K intake
and genetic polymorphisms [2], with over 40% of the vari-
ability explained by polymorphisms in the two genes
VKORC1 and CYP2C9 [3].
Less is known about the relative importance of
genetic, clinical and demographic factors on warfarin dose
variability in children, but data from small studies have
started to emerge. Nowak-Göttl et al. [4], studying 34
warfarin-treated children with a median age of 15 years
(range 1–19 years), found that age was the most impor-
tant determinant, explaining 31.2% of the variability in
dose requirement, while polymorphisms in VKORC1 and
CYP2C9 only explained 2.8% and 0.5%, respectively. In
contrast, Nguyen et al. [5] recently reported that, in 37
children with a mean age of 9.6 years (range 1.8–18.6
years), age explained only 12% and polymorphisms in
VKORC1 and CYP2C9 accounted for 47% and 5% of the
variability, respectively. A larger study by Moreau et al. [6]
involving 83 children with a mean age of 8.4 years (range
0.2–18 years), reported that height explained 48.1% of the
variability in dose requirement and polymorphisms in
VKORC1 and CYP2C9 accounted for 18.2% and 2%, respec-
tively. In the largest published pharmacogenetic study in
children reported by Biss et al. [7], including 120 children
with a median age of 11.7 years (range 1.7–18 years),
height was found to account for 29.8%, VKORC1 for 26.6%
and CYP2C9 for 12.8% of the variability in warfarin main-
tenance dose requirement. Hence, published results are
inconclusive with regard to the relative importance of
individual predictors.
Reported differences in the contribution of CYP2C9
and VKORC1 genotype to the variability in warfarin dose
requirement in children could partly be explained by dif-
ferences in minor allele frequencies between studies [8],
but also heterogeneity in study design and analysis
approaches [2], as well as the small sample sizes, which
cause uncertainty in reported point estimates for rare
covariate effects. True genotype–phenotype relationships
may also be obscured when analyzing data from studies in
infants and young children depending on the importance
of ontogeny on enzyme activity levels [9]. For some of
the polymorphically expressed CYPs, ontogeny has been
shown to play a major role in explaining interindividual
variability in enzyme activity in newborns and infants, and
makes the genotype–phenotype relationship less evident
in these age groups [9]. For the CYP2C9 enzyme published
data indicate complete maturation around 6 months of
age [10]. Corresponding information about the ontogeny
of the VKORC1 enzyme is lacking.
Adult patients who possess CYP2C9 and/or VKORC1
polymorphisms have been shown to be more sensitive to
warfarin and prone to supra-therapeutic INRs during war-
farin initiation [3, 11]. A recent study [12] reported that
these polymorphisms also play an important role in the
early response to warfarin therapy in children. Children
with at least one CYP2C9 variant allele had higher mean
peak INR values during the first week of therapy, and a
higher proportion of INR values above target range
during the first month of therapy, than children with wild-
type CYP2C9. Children with the VKORC1 −1639 A/A geno-
type had higher mean peak INR values and a tendency to
more INR values being above target range during the first
month of therapy than those with the G/A or G/G geno-
type [12].
Pharmacometric models developed on adult data are
increasingly being used to improve dose predictions in
children [13, 14]. Using a pharmacometric approach when
analyzing clinical data can alleviate many of the difficulties
encountered with data derived from studies in children. A
model-based approach can benefit from the possibility to
incorporate prior knowledge, and to pool data across
studies. The approach also enables use of sparse and
unstructured real-life data, rather than relying on data
derived from stringent clinical trial settings [15]. It is also
possible to bridge from an existing adult model to paedi-
atrics through the use of physiological principles that
acknowledge that adults and children are in some aspects
similar and not discrete subpopulations [13, 14, 16].
Pharmacometric modelling and simulation are also advo-
cated by regulatory bodies to support the selection of safe
and efficacious dosing regimens for children [17, 18].
We have previously developed a PKPD-based model
that describes the relationship between warfarin dose
and the International Normalized Ratio (INR) response in
adults [19, 20], and which takes into account variation in
pharmacokinetics (PK) due to age and CYP2C9 genotype,
and variation in pharmacodynamics (PD) due to VKORC1
genotype. By estimating allele effects rather than geno-
type effects, the model development is less sensitive to
small sample sizes since individuals with two variant alleles
are not required for estimation of rare genotype effects.
The individual genotype effect is obtained by simply
adding the estimated allele effects. We have theoretically
adapted the adult model [20] for use in children [21]
through allometric weight scaling of clearance and
volume of distribution [22], and addition of a published
maturation function for CYP2C9 enzyme activity [10] to
handle the influence of enzyme ontogeny in neonates and
infants [9]. External validation of the theoretically bridged
model on data from 64 children 0–18 years old showed
that the model overall performed well, but with a ten-
dency to over predict INR response, or underestimate the
dose, in children ≤2 years old [21].
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The main objective of the present study was to identify
and quantify major genetic, clinical and demographic
sources of warfarin dose variability in children using mod-
elling and simulation.
Methods
Patients and treatment data
Data from two observational warfarin studies in children
with underlying heart disease [7, 21] were used in the
current analysis. The two studies are only briefly described
here as relevant to this work. One study recruited 93 chil-
dren at four hospitals in the UK and 27 children at one
hospital in Canada; the other included 67 children from
four hospitals in Sweden. Warfarin was administered using
formulations available in the respective countries: 2.5 mg
tablets or extemporaneous 0.1 mg or 0.3 mg capsules in
Sweden, 1, 3 or 5 mg tablets in the UK, and 1, 2, 2.5, 3, 4, 5,
6, 7.5 or 10 mg tablets in Canada. Local ethics committees
approved the studies and informed consent was obtained
from patients 18 years or older or from parents of children
below 18 years.
Longitudinal treatment data were collected from hos-
pital records and patient charts, including information on
treatment indication, baseline INR, target INR, warfarin
doses, INRs, date of birth, height and total bodyweight.
All children were genotyped for VKORC1 −1639 G > A
(rs9923231), CYP2C9 *2 and *3 (rs1799853 and rs1057910)
and CYP4F2 *3 (rs2108622). The patients’ ethnic back-
ground was self-reported according to pre-specified
categories.
One hundred and sixty-three of the 187 children
enrolled had sufficiently detailed treatment records to
be included in the analysis. Seventy-eight children had
data available from treatment start. For the other 85
children a sufficiently long dosing history to ascertain
pharmacokinetic steady-state was required before INR
observations were included in the analysis. The assump-
tion on steady-state was based on CYP2C9 genotype and
predicted half-lives for S-warfarin, using the following set
of rules: at least 7 (*1/*1), 10 (*1/*2), 14 (*1/*3 or *2/*2) or
21 days (*2/*3) of dosing information before inclusion of
an INR (no *3/*3 included). The assumption was tested in a
sensitivity analysis by doubling the treatment length, with
no impact on the results, suggesting that the rules applied
were robust.
The measured effect of warfarin therapy is the change
in INR from baseline, i.e. if baseline INR is 1.0 and the meas-
ured INR is 2.8, the treatment effect is a ΔINR of 1.8. Base-
line INR was only available in 35 children and ranged from
1.0–1.7, with a median of 1.2. Attempts were made to esti-
mate baseline INR for those children where this was
missing, but the data were not informative enough to
separate baseline and EC50 when estimated simultane-
ously. Instead we used the observed baseline when avail-
able, and fixed it to the median value of 1.2 for children
with missing baseline values.
Model development
All modelling was performed in NONMEM, version 7 (ICON,
ICON Development Solutions, Ellicott City, MD, USA), using
the first order conditional estimation method with interac-
tion [23]. Analyses were carried out using an additive
residual error model on log-transformed data, and with
interindividual variability implemented using exponential
models. Model selection was guided by (i) the decrease in
the objective function value (the minimization criteria in
NONMEM), (ii) the condition number obtained from NONMEM,
(iii) graphical goodness-of-fit analysis in Xpose [24],
(version 4.3.5 [xpose.sourceforge.net]) and R (version
2.14.2 [www.r-project.org]), (iv) the estimated uncertainty
in parameter estimates as reported by the standard error
obtained from NONMEM, (v) simulation based diagnostics
(prediction corrected visual predictive checks (pc-VPCs))
and (vi) plausibility of parameter estimates. The difference
in the objective function value between two hierarchical
models is approximately χ2-distributed, meaning that a
nominal difference of 3.84 corresponds to a P value <0.05
for one degree of freedom. Criteria for final model selec-
tion included: (i) a statistically significant improvement
over a competing simpler model, (ii) a condition number
that was reasonably low (<1000), (iii) reasonable sized
standard errors, and with 95% confidence intervals not
including zero or unity (whatever applicable), (iv) pc-VPCs
showing good agreement between observed and model
predicted INRs and (v) biologically plausible estimates of
model parameters.
Base model
This work is a further development of our published adult
PKPD-based warfarin model with S-warfarin as the only
exposure predictor for INR response [20], or rather a
theoretically scaled version of this model for use in chil-
dren [21]. Scaling to children was achieved by adding
bodyweight to the adult model using allometric scaling
[22], and addition of a published maturation function for
CYP2C9 enzyme activity [10]. Both models are adapted
according to the KPD-framework, as described by Jacqmin
et al. [25]. This means that the models operate without PK
observations, but make use of available information about
variability in PK on a population level, e.g. the known influ-
ence of CYP2C9 genotype on the typical clearance (CL) of
S-warfarin. A drawback compared with a full PKPD-model
is that it becomes more difficult to separate remaining
sources of variability into PK and PD, respectively, and
hence less mechanistic interpretation can be made from a
KPD-model.
Equation 1 provides the general formula for the predic-
tion of clearance (CL) of S-warfarin as a function of age
(CYP2C9 enzyme ontogeny) and size (bodyweight), and
equation 2 provides the formula for the prediction of
A.-K. Hamberg et al.
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volume of distribution (V) of S-warfarin as a function of size
(bodyweight):
CL CL
BW
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AGE
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i
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i
i
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CLi and Vi represent the typical parameter values in an
individual with the bodyweight BWi, and CLs and Vs repre-
sent typical parameter values in an individual with the
bodyweight BWs. AGEi is the post-natal age expressed in
years of an individual with the bodyweight BWi. Using the
published maturation function, CYP2C9 enzyme activity in
a typical child is mature and reaches adult values at the
age of 6 months.
Figure 1 provides a schematic picture and a brief
description of the theoretically scaled warfarin model [21],
which served as the base model in this analysis.
Covariate selection
The base model included CYP2C9 genotype, bodyweight
and age as predictors of CL, bodyweight as predictor of
V and VKORC1 genotype as predictor of EC50. Additional
covariates tested when adapting and optimizing the
model for children included age, gender, bodyweight,
indication, time since treatment start, dose, and CYP4F2
genotype (tested as allele effects). Covariates were
screened for using scatter plots of individual parameter
estimates (K10 and EC50) against individual covariates, and
by generalized additive modelling (GAM) using Xpose [24].
Nested models were compared statistically using a likeli-
hood ratio test on the differences in objective function
value (OFV).
Model evaluation
VPCs were used to evaluate the predictive performance of
candidate models. The principle of a VPC is to assess
graphically whether simulations from a model are able to
reproduce both the central trend (the median curve) and
the variability (outer percentiles) in the observed data
when plotted against an independent variable (e.g. time,
age or bodyweight). A prediction corrected VPC (pc-VPC) is
a modification of the standard VPC that is appropriate to
apply on data collected in studies with an adaptive design
[26] as in the case with warfarin. All pc-VPCs were con-
structed based on 500 simulated replicates of the original
dataset design.
Predictions of maintenance dose
The final model was used to predict the warfarin mainte-
nance dose for typical children aged 2, 8 and 14 years old,
adopting the approach described by Jönsson & Karlsson
[27]. Briefly, this entails (i) defining a target steady-state
INR response, in our case 2.5, and (ii) using the model
Dose
Covariates in base model
CL: CYP2C9 allele effects,  AGE effect on 
CYP2C9 ontogeny, allometric WT scaling
V: allometric WT scaling
EC50:  VKORC1 allele effects 
Parameters with covariate effects
K10       = CL/V
DR       =  A * K10 = A * CL/V
EDK50  = CL * EC50
PK model PD model Transduction model Effect model
K10
A
C11 C12
MTT1 INR = INRBASE+INRMAX*(1–(C13+C23/2))
MTT2
C13
C21 C22 C23
E = 1–
Emax*DRγ
EDK50γ+DRγ
Figure 1
Schematic picture of the bridged warfarin model [21] used as base model in this study and a list of covariate effects included in the base model. The model
consists of a one compartment PK model that describes the relationship between warfarin dose and S-warfarin concentrations (PK), and an inhibitory
Emax-model to describe inhibition of the vitamin K cycle (PD), with S-warfarin as the only predictor of the anticoagulant response. Included also is a
transduction model that captures the time delay between the inhibition of the vitamin K cycle, and the decrease in functioning coagulation factors (II, VII,
IX and X), and finally an effect model that translates the decrease in functioning coagulation factors to an increase in INR. Compartment A represents
amount of warfarin in the body, K10 the rate constant governing drug elimination from the body but also distribution to the site of action, here denoted DR
for dose rate. EDK50, is the dose rate that results in 50% of the maximum effect Emax and MTT is the mean transit time through the transduction-model
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to estimate the dose required to achieve the target
response, conditioned on the population (mean) para-
meter estimates.
Results
Patient and treatment data
Of 187 children enrolled in the two warfarin studies [7, 21],
163 had sufficiently detailed data records to be included in
this analysis. Demographic information, including treat-
ment indication, target INR and genotype frequencies
for VKORC1 −1639 G > A (rs9923231), CYP2C9 *2 and *3
(rs1799853 and rs1057910) and CYP4F2 *3 (rs2108622) are
shown in Table 1. All genotypes were in Hardy–Weinberg
equilibrium. Age and weight for the entire study period
ranged from 0.06–18.9 years and 3.6–100.1 kg, respec-
tively. The median dose from all phases of therapy was
2.5 mg (range, 0.125–12.5 mg) or 0.112 mg kg−1 (range,
0.0156–0.585 mg kg−1), respectively. Self-reported ethnic
origin included 76.7% White, 7.4% Asian, 4.9% Black
African and 11% other. Treatment data varied in length
from 3 weeks up to 10 years per child, comprising a total of
6445 INR observations covering more than 183 treatment
years. Figure 2 provides a raw data plot of all INR observa-
tions per subject, showing the age span for which treat-
ment data were available. Coherent treatment records that
included data after a child had turned 18 years old were
also included in the analysis to increase the amount of
data per individual. There were in total 55 INR observa-
tions from seven subjects that were between 18 and
19 years old.
Final model
The theoretically scaled warfarin model [21] was used as
the base model in this analysis. All model parameters in
the base model, except the Hill factor in the Emax-model,
were re-estimated on the paediatric dataset. Data sup-
ported addition of two new covariates to the base model:
an exponential age-effect on the elimination rate constant
K10, and an exponential effect of time since treatment start
on EC50, the parameter describing sensitivity to warfarin.
The principal impact on K10 and EC50, respectively, are
shown in Equations 3 and 4:
K
V
10 6 31
6 3
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− −
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where θIncrease at age=6.3y describes the relative increase in K10 in
a 6.3 year old child and θHalf-life  age-effect on , K10 the half-life of
the age-effect on K10, and θDecrease at time = 0 describes the
decrease in EC50 at treatment start (time = 0) and
θHalf-life  time-effect on E, C50 the half-life of the time-effect on EC50.
This means that the model predicts that the elimination
rate of warfarin (K10) is higher than that predicted from
bodyweight (allometric weight scaling of CL and V) and
age (maturation function on CL). For example, at the age of
2 years the model predicts a K10 that would result in a
half-life of S-warfarin (t1/2 = ln2/K10) approximately five
times shorter than that predicted without this additional
age-effect. With the time effect on EC50, the model predicts
that children are more sensitive to warfarin at the start of
therapy, with an approximate 60% reduction of EC50. This
effect showed a half-life of 170 h (7 days), which means
that the effect disappears after approximately 4 weeks
(four half-lives) of therapy.
Table 1
Patient and clinical characteristics
Gender, n (% male/female) 105/58 (64/36)
Median age, years (range) 6.3 (0.066–19)
Median weight, kg (range) 20 (3.6–100.1)
CYP2C9 genotype, n (%)
*1/*1 116 (71.2)
*1/*2 20 (12.3)
*1/*3 23 (14.1)
*2/*2 2 (1.2)
*2/*3 2 (1.2)
*3/*3 –
VKORC1 genotype, n (%)
G/G 57 (35.0)
A/G 79 (48.5)
A/A 27 (16.5)
CYP4F2 genotype, n (%)
C/C 87 (53.4)
C/T 66 (40.5)
T/T 10 (6.1)
Treatment indication, n (%)
Fontan procedure 75 (46.0)
Prosthetic heart valve 34 (20.8)
Dilated cardiomyopathy 15 (9.2)
Coronary aneurysm 11 (6.7)
Other 28 (17.3)
Target INR, n (%)
2.0–3.0 119 (73.0)
2.5–3.5 32 (19.6)
Other (lower range <2 or upper range >3.5) 8 (4.8)
Missing 4 (2.5)
INR observations, n (%) assayed with
Owren based method 4298 (66.7)
Quick based method 2147 (33.3)
Total number of children, n (%) 163
Swedish study [21] 64 (39.3)
UK/Canadian study [7] 99 (60.7)
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When the two additional covariates were included
stepwise in a multivariate model, both remained
significant. Following a confirmatory backward stepping
approach, both remained significant, with a ΔOFV of 189
and 150 upon removal of the age-effect on K10 and the
time-effect on EC50, respectively. Also the objective func-
tion value dropped from −10586.8 in the base model to
−10906.1 in the final model, i.e. a ΔOFV of −319.3. The final
model parameters are reported in Table 2, together with
parameter estimates from the base model and adult
parameter values [21] as reference. The proportion of
unexplained variability in K10 dropped from 160% in
the base model to 124% in the final model, and the
residual error in INR response from 25.4% to 24.9%. ETA
shrinkage in K10 and EC50 was 37.1% and 8.6%, respectively.
As shrinkage in K10 was relatively high, post hoc plots were
only used for guidance and all covariate effects were
tested formally using the likelihood ratio test. The condi-
tion number was 250, which is reasonable and not indica-
tive of over-parameterization.
Attempts were made to re-estimate CYP2C9 allele
effects on CL in children. However, due to the nature of the
KPD model, with no input of drug concentrations, primary
PK parameters such as CL and V were unidentifiable. The
quantitative CYP2C9 allele effects on CL were therefore
assumed to be the same in children as previously esti-
mated for adults [20], an assumption that seems valid at
least for children older than 6 months when the enzyme is
expected to be fully matured. However, VKORC1 allele
effects on drug sensitivity were successfully re-estimated
in children. The quantitative effect was found to be very
similar in children and adults, with a two-fold difference in
dose between children with the G/G and A/A genotype.
This indicates that the VKORC1 enzyme is also matured at
an early age. The potential influence of genetic variation in
the CYP4F2 gene has not been tested in the adult warfarin
KPD-model. The gene codes for the CYP4F2 enzyme,
which is involved in the metabolism of vitamin K, and car-
riers of a variant allele have been suggested to require a
higher warfarin dose [28–30]. When CYP4F2 genotype was
tested as a predictor for dose variability in children, there
was a trend suggesting a 9% higher dose per T allele, but
with a symmetrical 95% confidence interval ranging from a
3% lower to a 21% higher dose per T allele, hence includ-
ing zero. In addition, the drop in OFV (−4.2) was only
borderline significant, and resulted in a model with a
condition number exceeding 2500, which is indicative
of over-parameterization. Taken together, this did not
support the retention of CYP4F2 genotype in the final
model.
Internal model evaluation
Figure 3 shows pc-VPCs of the final model, both with and
without stratification on age, and with stratification on
VKORC1 genotype shown in Figure 4. Additional VPCs with
stratification on CYP2C9 genotype or CYP4F2 genotype, or
without stratification but with bodyweight or age as the
independent variable, are included as Supporting Informa-
tion Figures S1 and S2. Overall the model performed well
in predicting the INR response in children, irrespective of
150
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Figure 2
Raw data plot of INR observations included in the analysis, and where the dots along the x-axis show the age span for which observations were available
per child. INR observations from several treatment periods in the same child are connected with a line. ID 1–99 represent children from the British/Canadian
study and ID 100–163 represent children from the Swedish study
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age, bodyweight, CYP2C9, VKORC1 or CYP4F2 genotype.
Observed INR values (Figure 4 and Supporting Information
Figure S1) also confirmed previous findings that children
with variant alleles have higher mean peak INR values at
the start of therapy than those with wild-type genotypes
[12].
Predictions of maintenance dose
Predicted maintenance doses for 54 typical children aged
2, 8 and 14 years old and with all possible combinations of
CYP2C9 and VKORC1 genotypes, a baseline INR of 1 and a
target INR of 2.5 are presented in Table 3. For example, the
model predicts a three-fold difference in maintenance
Table 2
Model parameters (%RSE) for (I) base model estimated in adults [21], (II) base model re-estimated in children and (III) final covariate model in children
(I) Base model with
parameters estimated
in adults
(II) Base model with
parameters estimated
in children
(III) Final covariate
model in children
Objective function value −10586.8 −10906.1
Structural model parameters
EC50 per VKORC1
- G allele (mg l−1) 1.62 (10) 2.05 (4.6) 2.02 (4.3)
- A allele (mg l−1) 0.770 (9.5) 0.91 (10.4) 0.997 (9.8)
MTT1 (h) 22.6 (3.3) 42.7 (18.7) 37.4 (0.6)
MTT2-MTT1 (h) 87.8 (5.8) 6.2 (295) 156 (6.6)
MTT2 (h)* 110 48.9 193
Hill factor (γ), Emax model 1.37 (4.9) 1.37 FIX 1.37 FIX
Age effect on K10
- Increase at age 6.3 years (%) 0.879 (35.5)
- Half-life, age-effect on K10 (years) 0.488 (3.9)
Time effect on EC50
- Decrease at time 0 (%) 61.7 (0.7)
- Half-life, time-effect on EC50 (h) 170 (6.8)
Interindividual variability parameters (%)
ωEC50 32 (4.3) 36 (6.6) 33.9 (6.4)
ωK10 42 (8.3) 159 (9.9) 124 (11.3)
Residual error parameters (%)
σINR 18 (1.7) 25.4 (0.3) 24.9 (0.3)
*MTT2 was not estimated but derived from MTT1 and MTT2-MTT1.
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Figure 3
Prediction corrected VPCs for the optimized model applied on data from warfarin treated children. The panel to the left represents data from all children
and the three panels to the right after stratification into three age groups; ≤2 years, >2 and <12 years, and ≥12 years. Solid lines denote the medians of
observed data and dashed lines denote the 10th and 90th percentiles of observed data. Shaded areas represent 95% confidence intervals of simulated
medians (grey) and 80% prediction intervals (pink). A model is considered to have good predictive properties if the lines representing the observed data
mainly fall inside the simulated confidence intervals
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dose between a typical 2-year-old with a bodyweight of
13 kg and a 14-year-old with a bodyweight of 52 kg, con-
ditioned on the same genotype combinations, despite a
four-fold difference in bodyweight. For two children with
the same age, bodyweight and CYP2C9 genotype, the
model predicts approximately a two-fold difference in
dose between a child carrying the VKORC1 −1639 G/G
genotype and a child homozygous for the variant A allele.
For two children who differ only in CYP2C9 genotype, the
model predicts approximately a four-fold difference in
dose between subjects having the wild-type genotype
(CYP2C9*1/*1) and those being homozygous for the *3
allele (CYP2C9*3/*3). Predicted maintenance doses were
10–12% lower if the baseline INR was 1.2 instead of 1, and
25–30% higher if the target INR was set to 3 instead of 2.5.
Discussion
This is the largest study to date, which has evaluated
the effect of genetic, clinical and demographic factors on
warfarin dose variability in children. Despite warfarin
being increasingly used to treat thromboembolic disor-
ders in children, the number of children treated and eligi-
ble for pharmacogenetic studies is still limited. Novel
approaches, such as modelling and simulation that can
incorporate prior knowledge and pool data across studies,
have been promoted as one way to improve the quality
and robustness of analysis in small patient populations. To
our knowledge this is the first time that data from warfarin
treated children have been analyzed using modelling and
simulation.
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Figure 4
Prediction corrected VPCs but with data stratified on VKORC1 genotype, with from left to right VKORC1 G/G (decreased sensitivity to warfarin), VKORC1 A/G
(intermediate sensitivity to warfarin) and VKORC1 A/A (increased sensitivity to warfarin)
Table 3
Model predicted warfarin maintenance doses in mg (mg kg−1) for typical children 2, 8 or 14 years old, and with different combinations of CYP2C9 and
VKORC1 genotypes, all with a baseline INR of 1 and a target INR of 2.5. The following bodyweights were assumed for a 2, 8 and 14-year-old: 13 kg, 26 kg and
52 kg, respectively
VKORC1 G/G VKORC1 A/G VKORC1 A/A
CYP2C9
2 years 8 years 14 years 2 years 8 years 14 years 2 years 8 years 14 years
(13 kg) (26 kg) (52 kg) (13 kg) (26 kg) (52 kg) (13 kg) (26 kg) (52 kg)
*1/*1 2.74 5.00 8.43 2.05 3.73 6.29 1.35 2.47 4.16
(0.211) (0.192) (0.162) (0.158) (0.144) (0.121) (0.104) (0.095) (0.080)
*1/*2 2.11 3.78 6.35 1.57 2.82 4.74 1.04 1.86 3.13
(0.162) (0.145) (0.122) (0.121) (0.108) (0.091) (0.080) (0.072) (0.060)
*1/*3 1.76 3.11 5.24 1.32 2.32 3.91 0.87 1.53 2.58
(0.135) (0.120) (0.101) (0.101) (0.089) (0.075) (0.067) (0.059) (0.050)
*2/*2 1.45 2.54 4.27 1.08 1.89 3.19 0.72 1.25 2.11
(0.112) (0.098) (0.082) (0.083) (0.073) (0.061) (0.055) (0.048) (0.040)
*2/*3 1.09 1.87 3.15 0.81 1.40 2.35 0.54 0.92 1.56
(0.084) (0.072) (0.061) (0.062) (0.054) (0.045) (0.041) (0.036) (0.030)
*3/*3 0.71 1.21 2.04 0.53 0.90 1.52 0.35 0.60 1.01
(0.055) (0.047) (0.039) (0.041) (0.035) (0.029) (0.027) (0.023) (0.019)
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We have previously developed a PKPD-based warfarin
model from large adult patient populations using popula-
tion modelling. This model has now been updated and
optimized for use in children. A major advantage of
analyzing data using population modelling is that all avail-
able observations can be used in the analyses, irrespective
of when during treatment data were collected (at treat-
ment start, during stable anticoagulation or following
dose revisions). To get accurate and reliable results it is
imperative that the dose history is correctly reproduced,
but this holds true regardless of the method of analysis. In
the majority of published warfarin studies in both adults
and children, only treatment data from a single time point
at a period of stable anticoagulation are included in the
analysis. This is likely to introduce a selection bias by
excluding the patients who are the most difficult to treat,
and also leads to a poor utilization of available treatment
data. The definition of stable anticoagulation also varies
between studies [2], which further complicates interpreta-
tion and comparability of study results. In the current
analysis, treatment data from 163 warfarin treated children
have been used, including data from all phases of therapy,
and representing over 183 treatment years, i.e. on average
>1 treatment year/child. A limitation might on the other
hand be that our study was restricted to mainly Caucasian
children (77%), all with congenital or acquired heart
disease. However, the homogeneity of our study popula-
tion enabled us to detect an increased sensitivity to war-
farin at the start of therapy (as a time-effect on EC50). This is
in line with results reported by Moffett et al. who discov-
ered that cardiac surgery was a risk factor for elevated INR
values in children starting warfarin therapy, with an odds
ratio of 4.1 (95% CI 1.5, 11.6) [31]. Rahman et al. also
reported an increased sensitivity to warfarin at the start of
therapy in adults undergoing heart valve replacement. The
mean maintenance dose (1–3 months after surgery) was
43% higher than the mean initiation dose (5.09 vs. 3.55 mg;
P < 0.001) [32]. It can therefore be speculated that both
children and adults undergoing major surgery are more
sensitive to warfarin. Reasons for this could be temporary
physiological changes after major surgery that may influ-
ence the PK and/or PD of warfarin, combined with a
decreased appetite and a lower intake of vitamin K post-
operatively. Lack of physical activity postoperatively may
also influence dose requirements, since it has been shown
that increased physical activity may lead to increased war-
farin dose requirements in adults [33].
The most common way to report the contribution of
individual factors to warfarin dose requirement is by esti-
mating the percentage in dose variability explained by a
given factor [3–7]. However, the clinical utility of this
measure, when evaluating predictors important for indi-
vidualized dosing, may be questioned. The percentage of
variability explained by a given factor is a measure of what
is most important for the overall variability in the popula-
tion, and takes into account the effect size of a given factor
and also how common this factor is in the study popula-
tion. For dose prediction on an individual basis, a more
relevant measure would be how much a given factor can
influence the dose in an individual patient. VKORC1 is
usually ascribed a more important role on a population
level due to the fact that VKORC1 polymorphisms are more
common than CYP2C9 polymorphisms in most popula-
tions [8]. However, we have previously shown that
polymorphisms in the VKORC1 gene typically explain up to
a two-fold difference in warfarin dose in adult patients,
while the difference in dose between typical individuals
with different CYP2C9 genotypes can be up to 4.2-fold.
With the optimized pharmacometric model for children
we demonstrate that CYP2C9 and VKORC1 genotypes also
have comparable quantitative effects on dose variability in
children.
Evidence that the CYP4F2 genotype can influence war-
farin dose requirement was first presented in 2008 [28] and
later confirmed by others [29, 30]. However, it has been
questioned whether the contribution of CYP4F2 is suffi-
cient for inclusion in pharmacogenetic dosing algorithms
[34]. In our study we found a 9% increase in warfarin dose
per CYP4F2 T (*3) allele, but with the 95% CI ranging from
a 3% reduction to a 21% increase in dose per T allele. The
relatively small effect, together with poor precision in the
estimate that also included zero, did not support retention
of the CYP4F2 genotype in the final model. This is also in
agreement with results reported by Moreau et al. [6] and
Biss et al. [7], who found no association between warfarin
maintenance dose and CYP4F2 genotype in children.
A general dosing recommendation in children is to
adjust the warfarin dose according to bodyweight [1, 4, 5].
The final model also supports that individual dose require-
ments are dependent on bodyweight, but that the rela-
tionship is non-linear. For example, the model only
predicts a three-fold difference in dose (in mg) for a four-
fold difference in bodyweight, which means that if adult
doses are linearly scaled to children this will lead to under-
dosing. This is in line with findings from other warfarin
studies in children, which have concluded that a higher
weight-normalized dose is required, especially in the
younger age groups [35, 36].
The model-predicted maintenance dose for typical
children 2, 8 and 14 years old ranged from 0.019 mg kg−1 to
0.21 mg kg−1 (Table 3). This should be compared with
observed maintenance doses of warfarin in children,
which are reported to range from 0.03 to 0.39 mg kg−1
by Nowak-Göttl et al. [4], from 0.04 to 0.32 mg kg−1 by
Nguyen et al. [5], from 0.03 to 0.50 mg kg−1 by Moreau
et al. [6], from 0.02 to 0.43 mg kg−1 by Biss et al. [7], and
from 0.04 to 0.29 mg kg−1 by Hamberg et al. [21]. The upper
range of model-predicted warfarin doses was hence
lower (0.21 mg kg−1) than reported in these five studies
(0.50 mg kg−1). However, this is not unexpected since the
model-predicted doses are conditioned on a target INR
of 2.5 and limited to children 2–14 years old, whereas
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observed doses also included children with a higher target
INR and a broader age range (3 months–18.6 years). In
addition, the model-predicted doses presented here only
represent typical doses and do not take the unexplained
between-subject variability into account. Overall the
agreement between model-predicted and observed main-
tenance doses appeared to be good.
In conclusion, we have developed the first PKPD-based
pharmacometric model that provides quantitative esti-
mates of genetic, clinical and demographic sources of war-
farin dose variability in children. The impact of genotype
on dose variability in children was found to be comparable
with what has been reported for adults, with CYP2C9
explaining up to a four-fold difference in dose (CYP2C9
*1/*1 vs. *3/*3) and VKORC1 explaining up to a two-fold
difference in dose (VKORC1 G/G vs. A/A), respectively.
Bodyweight, age, baseline and target INR, and time since
initiation of therapy, but not CYP4F2 genotype, were also
found to influence significantly typical warfarin dose
requirements in children. The dependence of warfarin
dose requirements on bodyweight is non-linear, and an
increased sensitivity to warfarin at the start of therapy can
be speculated to only be present after major surgery.
The model provides the basis for development of a
computerized tool for a priori and a posteriori dose-
individualization in the pursuit of improving efficacy and
safety of warfarin therapy in children. A prototype for a
dose individualization tool has already been developed for
adults [37]. Our dosing model should now be validated
and prospectively evaluated to determine whether it will
aid effective and safe warfarin therapy in children. A
randomized, controlled clinical trial against standard-of-
care would be the ultimate way to investigate if the model
could improve INR control in warfarin treated children.
However, this is a huge task and is probably best done
through an international collaboration that includes chil-
dren with a diverse clinical and ethnic background.
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Figure S1
Prediction corrected VPCs for the optimized model
applied on data from 163 children but stratified on (A)
CYP2C9 genotype or (B) CYP4F2 genotype. Figure 1A
includes from left to right data from children with CYP2C9
*1/*1 (high enzyme activity), CYP2C9 *1/*2 or *1/*3 (inter-
mediate enzyme activity) and CYP2C9 *2/*2, *2/*3 or *3/*3
(low enzyme activity). The right panel, representing chil-
dren with rare CYP2C9 genotypes, includes data from only
four children and results in wide prediction intervals that
overlap. Figure 1B includes from left to right data from
children with CYP4F2 *1/*1 (wild-type), CYP4F2 *1/*3 (one
variant allele) and CYP4F2 *3/*3 (two variant alleles). There
is no systematic bias in the VPCs suggesting that a child
with the CYP4F2 variant allele requires a higher warfarin
dose
Figure S2
Prediction corrected VPCs for the optimized model
applied on data from 163 warfarin treated children but
using body weight (A) or age (B) as the independent vari-
able (x-axis) instead of time. Solid lines denote the
medians of observed data and dashed lines denote the
10th and 90th percentiles of observed data. Shaded areas
represent 95% confidence intervals of simulated medians
(grey) and 80% prediction intervals (pink). A model is
considered to have good predictive properties if the lines
representing the observed data mainly fall inside the simu-
lated prediction intervals
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